-+ 0.00%
-+ 0.00%
-+ 0.00%

Arcellx Announces Its Late-breaking Abstract For Its Novel For Its D-Domain Binder In Anitocabtagene Autoleucel Accepted For Presentation At 2026 Tandem Meetings

Benzinga·02/04/2026 14:07:06
Listen to the news

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that a late-breaking abstract for its novel D-Domain binder in anitocabtagene autoleucel (anito-cel) has been accepted for presentation at the 2026 Tandem Meetings. BCMA-directed CAR T therapies are effective in treating relapsed and/or refractory multiple myeloma, with the potential for deep and durable responses. Anito-cel is partnered with Kite, a Gilead Company.